Top

Published in:

01-10-2007 | Original Article

Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis

Authors: Rim Sghiri, Elyes Bouagina, Hela Zaglaoui, Hajer Mestiri, Latifa Harzallah, Imed Harrabi, Mehdi Ghannouchi, Faycel Mokhtar, Ibtissem Ghedira

Published in: Rheumatology International | Issue 12/2007

Abstract

To evaluate the rheumatoid arthritis (RA) diagnostic performances of anti-cyclic citrullinated peptide antibodies (anti-CCP). Anti-CCP was detected by an enzyme linked immunosorbent assay in 164 patients with RA and 343 controls. In addition, anti-CCP predictive value for radiological damage were investigated in 37 recent-onset RA patients followed up prospectively for 2 years. Radiological damages were assessed by Sharp method modified by van der Heijde. The sensitivity of anti-CCP was 78.7% and the specificity was 95.6%. The positive predictive value and the negative predictive value were 90.2% and 90.3%, respectively. Anti-CCP were detected in sera of 79.3% of patients with recent onset RA and 78.3% of patients with long disease duration. In univariate and multivariate analyses, anti-CCP were not predictive for radiological damage. Our study confirms the high diagnostic performances of anti-CCP in RA. They are very useful to aid the diagnostic of RA in clinical practice.

Pincus T (1998) Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis 47:2–7PubMed

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef

van Schaardenburg D, Lagaay AM, Otten HG, Breedveld FC (1993) The relation between class-specific serum rheumatoid factors and age in the general population. Br J Rheumatol 32:546–549PubMedCrossRef

Aho K, Palusuo T, Kurki P (1994) Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum 23:379–387PubMedCrossRef

Niehuis RLF, Mandema EA (1964) A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 23:302–303

Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, Serre (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679PubMed

Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, Dutoit V, Fauchais AL, Hachulla E, Flipo RM, Prin L (2004) Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63:415–419PubMedCrossRef

Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRef

van der Heijde DM, van Riel PL, van Leeuwen MA, van ‘t Hof MA, van Rijswijk MH, van de Putte LB (1992) Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 31:519–525PubMedCrossRef

10.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281PubMedCrossRef

11.

Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089–1093PubMed

12.

Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, Takemura M, Takasaki Y, Mimori T, Yamamoto K (2003) High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 32:197–204PubMedCrossRef

13.

Sauerland U, Becker H, Seidel M, Schotte H, Willeke P, Schorat A, Schluter B, Domschke W, Gaubitz M (2005) Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann N Y Acad Sci 1050:314–318PubMedCrossRef

14.

Correa PA, Tobon GJ, Citera G, Cadena J, Schneeberger E, Camargo JF, Maldonado-Cocco JA, Anaya JM (2004) Anti cyclic citrullinated antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1. Biomedica 24:140–152PubMed

15.

Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65:845–851PubMedCrossRef

16.

Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef

17.

Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef

18.

Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef

19.

Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-Goksel A, Saribas S, Arisoy N, Kocazeybek B (2004) Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 63:1687–1689PubMedCrossRef

20.

Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL (2004) Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 31:1829–1833PubMed

21.

Brunner J, Sitzmann FC (2006) The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2:449–451

22.

van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, Dijkmans B, van Venrooij WJ (2003) Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 30:825–828PubMed

23.

Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, Mielants H, Veys EM, Baeten D, De Keyser F (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64:1145–1149PubMedCrossRef

24.

Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C (2005) Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32:511–515PubMed

25.

Inanc N, Dalkilic E, Kamali S, Kasapoglu-Gunal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17–23

26.

Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ (2001) Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 60:67–68PubMedCrossRef

27.

Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, Labarre C, Meyer O, Sibilia J, Mariette X (2005) Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren’s syndrome. Ann Rheum Dis 64:114–117PubMedCrossRef

28.

Tobon GJ, Correa PA, Anaya JM (2005) Anti-cyclic citrullinated peptide antibodies in patients with primary Sjogren’s syndrome. Ann Rheum Dis 64:791–792PubMedCrossRef

29.

Wener MH, Hutchinson K, Morishima C, Gretch DR (2004) Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 50:2305–2308PubMedCrossRef

30.

Sene D, Ghillani-Dalbin P, Limal N, Thibault V, van Boekel T, Piette JC, Cacoub P (2006) Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren’s syndrome. Ann Rheum Dis 65:394–397PubMedCrossRef

31.

Symmons D, Harrison B (2000) Early inflammatory polyarthritis: results from the norfolk arthritis register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis. Rheumatology 39:835–843PubMedCrossRef

32.

Scott DL (2000) Prognostic factors in early rheumatoid arthritis. Rheumatology 39(Suppl 1):24–29PubMed

33.

Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126PubMedCrossRef

34.

Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA (2003) The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 30:1691–1695PubMed

35.

Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680PubMedCrossRef

36.

Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095PubMedCrossRef

37.

Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef

38.

Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835PubMedCrossRef

Title: Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis
Authors: Rim Sghiri
Elyes Bouagina
Hela Zaglaoui
Hajer Mestiri
Latifa Harzallah
Imed Harrabi
Mehdi Ghannouchi
Faycel Mokhtar
Ibtissem Ghedira
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 12/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-007-0351-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2007

Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis

Epidemiological multicenter study on osteoporosis: the EDMUSTO study

Ankylosing spondylitis in a patient with Turner syndrome: a case report

Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab

Development of acute inflammatory arthritis by granulocyte-macrophage colony-stimulating factor during autologous stem cell transplantation for cryoglobulinemia

Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page